Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × tafasitamab × 90 days × Clear all

Phase

Phase 2 6 Phase 1/2 2 Phase EARLY_PHASE1 1 Phase 3 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 1

Interventions

pembrolizumab 137 Carboplatin 129 Cisplatin 123 Paclitaxel 94 Gemcitabine 92 Specimen Handling 81 Magnetic Resonance Spectroscopy 77 Docetaxel 70 Pemetrexed 65 Cyclophosphamide 63 Dexamethasone 61 Capecitabine 58 Radiotherapy 55 Doxorubicin 54 Oxaliplatin 52 Bevacizumab 51 durvalumab 48 Radiation 46 Fluorouracil 44 Vincristine 42 Rituximab 42 Leucovorin 41 Lenalidomide 41 130-nm albumin-bound paclitaxel 37 atezolizumab 35 Nivolumab 34 Letrozole 34 Irinotecan 31 Etoposide 31 Prednisone 30

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04824092 2026-04-01

frontMIND

Incyte Corporation

Phase 3 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡